학술논문
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Document Type
Article
Author
van den Bent, Martin J; Baumert, Brigitta; Erridge, Sara C; Vogelbaum, Michael A; Nowak, Anna K; Sanson, Marc; Brandes, Alba Ariela; Clement, Paul M; Baurain, Jean Francais; Mason, Warren P; Wheeler, Helen; Chinot, Olivier L; Gill, Sanjeev; Griffin, Matthew; Brachman, David G; Taal, Walter; Rudà, Roberta; Weller, Michael; McBain, Catherine; Reijneveld, Jaap; Enting, Roelien H; Weber, Damien C; Lesimple, Thierry; Clenton, Susan; Gijtenbeek, Anja; Pascoe, Sarah; Herrlinger, Ulrich; Hau, Peter; Dhermain, Frederic; van Heuvel, Irene; Stupp, Roger; Aldape, Ken; Jenkins, Robert B; Dubbink, Hendrikus Jan; Dinjens, Winand N M; Wesseling, Pieter; Nuyens, Sarah; Golfinopoulos, Vassilis; Gorlia, Thierry; Wick, Wolfgang; Kros, Johan M
Source
In The Lancet 7-13 October 2017 390(10103):1645-1653
Subject
Language
ISSN
0140-6736